Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment
- 20 February 2023
- journal article
- research article
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 135 (13-14) , 375-382
Abstract
Summary Aims Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce and maybe affected by co-payment of patients. The aim of this study was to elucidate PCSK9i treatment adherence in a setting of full cost coverage as it is the case in a number of European countries. Methods and results Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved and analyzed. A gap of ≥ 60 days between prescriptions was defined as treatment discontinuation. Patient adherence was evaluated as the proportion of days covered (PDC) over the observation period and treatment discontinuation rates were investigated by the Kaplan-Meier method. The mean PDC was 81.8% and was significantly lower in female patients. A PDC of ≥ 80% indicating adequate adherence was found in 73.8%. Of the study population 27.4% discontinued PCSK9i treatment and 49.2% thereof re-initiated treatment during the observation period. Most of the patients who discontinued treatment did so within the first year. Male patients and patients under 64 years showed significantly lower discontinuation and higher re-initiation rates. Conclusion Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patients this highly effective treatment is well-accepted as a long-term treatment.Keywords
This publication has 31 references indexed in Scilit:
- Influence of Patient Sex and Gender on Medication Use, Adherence, and Prescribing Alignment with GuidelinesJournal of Women's Health, 2014
- Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic DatabasesMedical Care, 2013
- How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?Current Atherosclerosis Reports, 2012
- The PCSK9 decadeJournal of Lipid Research, 2012
- Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysisCanadian Journal of Cardiology, 2012
- Predictors of Nonadherence to Statins: A Systematic Review and Meta-AnalysisAnnals of Pharmacotherapy, 2010
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 2009
- Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary preventionBritish Journal of Clinical Pharmacology, 2005
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003